

APHAR 2024



28th Meeting of the Austrian Pharmacological Society

23 – 25 September 2024
I N N S B R U C K
CCB, Campus Innrain

www.aphar.at



Photo CCB: © Uni Innsbruck


APHAR 2024

Programme

General Information

Date: 23– 25 September 2024

Location: CCB Centrum für Chemie und Biomedizin
Campus Innrain
Innrain 80-82, 6020 Innsbruck



Registration: Please pay your registration fee at the meeting registration desk (next to lecture room L.EG.220, CCB, ground floor)
Registration fees:

Member rate¹⁾: 50 €¹⁾

Non-member rate: 85 €

Student rate^{*)}: 25 €^{*)}

¹⁾Members of the Austrian Pharmacological Society

^{*)}Reduced registration fees for students only upon presentation of the student confirmation form

(<http://www.aphar.at/2023/student2024.docx>)

Participation is free of charge for APHAR Honorary members and invited plenary speakers.

Opening hours for Travel Grants and DFP attendance lists:

Mon 23 Sept: 13:00–18:00;

Tue 24 Sept: 08:00–12:00

CME credits: The event is registered with the Austrian Medical Chamber with **18 CME credits** (DFP Diplomfortbildungspunkte) (ID: [813063](#)).
Members of the Austrian Medical Association please bring your doctor's ID and enter your ID number into the attendance lists each day at the registration desk. The organisers will credit the points into your DFP account after the meeting.



Presentations: All presentations shall be given in **English**.

Short oral communications:

The presentation should be **10 minutes**, followed by a **5 min** discussion.

The lecture room is equipped for presentations with PowerPoint (PC format). Speakers may upload their presentation to the computer in the lecture hall using a USB stick. A laptop can only be connected using an VGA connection. A USB-C→VGA adapter is available. However, HDMI or display port connections are *not* possible, unfortunately.

Poster presentations:

Posters shall be mounted on the first day of the meeting prior to the start of the program and should be left on display for both days of the meeting. Poster dimensions: max. **A0 portrait format** (height: 119 cm; width: 84 cm).

Presenting authors must attend their posters during the designated poster session. **Guided poster tours** will take place during these session as indicated in the program. Authors should present their work in **3–5 min** (maximum) to allow time for discussion.

Abstracts: Published abstracts will appear in *Intrinsic Activity*, 2024; 12(Suppl.1)
<http://www.intrinsicactivity.org/2024/12/S1> (doi:[10.25006/IA.12.S1](#))
(Publications date: 16 September 2024)

INTRINSIC ACTIVITY

Social Program: Riverside Barbecue Dinner: Details to be announced.
Participation is free of charge for registered participants; extra tickets can be purchased at the registration desk.

Contact: E-mail for enquiries concerning the meeting: joerg.striessnig@uibk.ac.at
E-Mail for enquiries concerning abstract publication: thomas.griesbacher@medunigraz.at

APHAR 2024

Mo 23 Sept

13:00–18:00 *Registration* (next to lecture room L.EG.220, CCB, ground floor)

13:00–15:30 **Workshop: Regulatory aspects of drug development** (Eva Maria ZEBEDIN, Vienna)
Room: **L.03.112** (CCB, 3rd floor, Pharmacology)

Part 1

13:00–14:15 Lecture (basic overview)

14:15–14:30 Hands-on experience ATMP development

14:30–14:45 Q&A

Part 2

14:45–15:00 Group work: you are drug developers

15:00–15:15 Group work, discussion and review of group work

15:15–15:30 Open discussion

Participation is included in the registration fee of the meeting, but please register for this workshop by sending an informal e-mail to eva-maria.zebedin@meduniwien.ac.at

15:30–17:30 **GPMed Meeting** - Chair: Markus ZEITLINGER (Vienna)
Room: **L.EG.220** (CCB, ground floor)

15:30–16:00 **Univ.-Prof. Dr. Günter Weiss** (Univ.-Klinik für Innere Medizin 2, Innsbruck):
Klinische Forschungsprojekte der Medizinischen Universität Innsbruck – Schwerpunkt Infektiologie

16:00–16:30 **Univ.-Prof. Dr. Dominik Wolf** (Univ.-Klinik für Innere Medizin 5, Innsbruck):
Klinische Studien: Zwischen Wünschen und Zwängen

16:30–17:00 **Univ.-Prof. Dr. Axel Bauer** (Univ.-Klinik für Innere Medizin 3, Innsbruck):
Digitales Vorhofflimmer-Screening – Können wir Schlaganfälle verhindern?

17:00–17:30 **Christoph Bittner** (Novartis Pharmaceutical Manufacturing GmbH, Kundl):
Biopharmazeutika: Entwicklung und Produktion in Tirol für die Welt

For the GPMed Meeting, the participation is free of charge for registered participants of the APHAR Symposium

Evening Plenary Lecture Chair: Thomas STOCKNER (Vienna)

18:00–18:45 **Klaus Liedl** (Innsbruck):
Rational strategies to overcome challenges in therapeutic antibody development

End of Day 1 (Dinner on own)

APHAR 2024

Tue 24 Sept

08:00–12:00 *Registration*
All lectures are in room **L.EG.220** (CCB, ground floor)

08:30–08:35 *Welcome*

08:35–08:45 **Veronika Sexl**, Rektorin der Leopold-Franzens Universität Innsbruck
Opening of the Meeting

Opening Session (Signaling in Haematopoietic Tumours) *Chair: Veronika SEXL (Innsbruck) & Eva ZEBEDIN-BRANDL (Vienna)*

08:45–09:10 **Dagmar STOIBER-SAKAGUCHI** (Krems)
STAT3 in haematopoietic disease

09:10–09:35 **Karoline KOLLMANN** (Vienna)
CDK6 in haematopoiesis and haematopoietic disease

09:35–10:00 *Coffee Break*

Plenary Lecture 1 *Chair: Andreas LIEB (Innsbruck)*

10:00–10:45 **Tawfeeq SHEKH-AHMAD** (Jerusalem, Israel)
CNS-targeted Antioxidant Gene Therapy for Treating Epilepsy

10:45–11:00 *Short Break*

Oral Presentations 1 (Neurons, Ion Channels) *Chair: Christoph SCHWARZER (Innsbruck)*

11:00–11:15 **Anna Madlmayer** (Linz):
TRPM7 regulates human T-cell activation and signaling

11:15–11:30 **Stefanie Geisler** (Innsbruck):
Genetic deletion of *Stac2* affects electrical activity of chromaffin cells and mouse behavior

11:30–11:45 **Jessica Marksteiner** (Wien):
Abnormally reduced Na⁺ currents in dystrophin-deficient ventricular cardiomyocytes are rescued by tenascin-C inhibition

[A1.1](#)

11:45–13:30 *Lunch Break*

Plenary Lecture 2 *Chair: Harald SITTE (Vienna)*

13:30–14:15 **Jürgen BROCKMÖLLER** (Göttingen)
About the known and about the unknown polyspecific organic cation transporters

Oral Presentations 2 (Signaling) *Chair: Florian REICHMANN (Graz)*

14:15–14:40 **Rainer SCHINDL** (Graz):
Continuous ionotropic chemotherapy reduces brain tumor growth

14:40–14:50 *Short Break*

14:50–15:05 **Mohammad N. ISLAM** (Wien):
Unlocking the potential of partial efficacy: a novel insight into monoamine neurotransmitter transporters

15:05–15:20 **Valentina KUGLER** (Innsbruck):
Kinases in motion: impact of protein and small molecule interactions on kinase activity conformations

15:20–15:35 **Juliana SCHWANZER** (Graz):
Basement membrane-derived matrikines in pulmonary inflammation

[A1.2](#)

15:35–17:00 **Poster and Coffee: Poster Session 1**
Guided Poster Tour

See next page for list of posters presented in this tour

17:00–18:45 **APHAR General Assembly**
(Members of APHAR only)

19:00 **Riverside Barbecue Dinner**
(included in the registration fee)

☞ abstracts numbered A... are published in [Intrinsic Activity, 2024; 12 \(Suppl. 1\) \(doi.org/10.25006/IA.12.S1\)](https://doi.org/10.25006/IA.12.S1)

Tue 24 Sept

15:35–17:00

Poster and Coffee: Poster Session 1

[Guided Poster Tour 1](#)

Board 2	Thomas ANGENOORTH (Vienna): Interactions of quinone derivates with human organic cation transporters 1–3 and plasma membrane monoamine transporter: implications for antimalaria drug pharmacokinetics
Board 4 A2.2	Daniele COLOMBO (Vienna): The transport cycle of the norepinephrine transporter
Board 6 A2.3	Nikola DENDA (Novi Sad): Hepatoprotective activity of silymarin in paracetamol-induced oxidative stress
Board 8	Isabella FAIMANN (Graz): Environmental enrichment reduces anxiety-like behaviour and changes the microbial community composition of mice
Board 10 A2.6	Matthias GANGLBERGER (Innsbruck): Pathogenic Cav1.4 variants differentially affect retinal pathways
Board 12	Jasmin GATTRINGER (Vienna): Design of a stabilized peptide drug to modulate immune cell migration in autoimmune disorders
Board 14 A2.7	Srdan GOVEDARICA (Novi Sad): Cardioprotective and antioxidant potential of silymarin in paracetamol-induced cardiotoxicity in rats
Board 16	Eva GRUDEN (Graz): Investigating IL-37 as a potential therapeutic option in eosinophilic esophagitis
Board 18	Simon HASINGER (Vienna): Investigating IL-37 as a potential therapeutic option in eosinophilic esophagitis
Board 20 A2.10	Martin HOHENEGGER (Vienna): The SOS1 / Ras interaction inhibitor BAY-293 impairs growth, migration and viability in human melanoma cells from different growth phases
Board 22	Nina KASTNER (Vienna): Bioisosteric replacement of the methylenedioxyphenyl group with 1,3-benzoxathiole creates two novel MDMA analogues with improved properties
Board 24 A2.13	Nino KOBAKHIDZE (Innsbruck): Hypercapnia-induced behavioral inhibition and its underlying neuronal mechanisms in a mouse model of autism spectrum disorder
Board 26 A2.14	Diksha KUNJ (Vienna): Elucidating the molecular basis of disease in human noradrenaline transporter variants
Board 28 A2.15	Martin LUTNIK (Vienna): Dapagliflozin prevents vascular ischemia-reperfusion injury in healthy young males: a randomized, placebo-controlled, double-blind trial
Board 30 A2.17	Nikola MARTIĆ (Novi Sad): In silico and in vivo analysis of the antidiabetic properties of carob extract
Board 32	Giulia PETRACCO (Graz): Sex-based differences in a mouse model of experimental colitis housed in environmental enrichment
Board 34 A2.19	Michaela PRCHAL-MURPHY (Vienna): Repurposing of treprostinil and cinacalcet to facilitate hematopoietic cell transplantation
Board 36 A2.20	Elisa ROTH (Innsbruck): Mouse retinal rod bipolar cells express different L-type Ca²⁺ channel transcripts
Board 38	Sivarkumar SRINIVASAN (Vienna): Transient dopamine depletion increases vesicular glutamate transporter 2 (VGLUT2) expression in midbrain dopamine neurons – implications for Parkinson's disease
Board 40	Thomas STOCKNER (Vienna): Characterization of the role of the third ion binding site in the GABA transporter BGT-1
Board 42	Olga TROVATO (Innsbruck): Structural determinants of dopamine receptor agonist selectivity
Board 44 A2.24	Didem ÜN (Vienna): GPR88: a potential drug target for neuroregeneration?
Board 46	Dominik WINDISCH (Vienna): Novel gut-stable peptide ligands targeting melanocortin MC4 receptors for the treatment of metabolic disorders

☞ abstracts numbered A... are published in [Intrinsic Activity, 2024; 12\(Suppl. 1\) \(doi.org/10.25006/IA.12.S1\)](#)

APHAR 2024

Wed 25 Sept

Plenary Lecture 2 Chair: Romual BELLMANN (Innsbruck)

08:30–09:15

Timon ADOLPH (Innsbruck)

Microbiome-based therapies in gastroenterology: What is the evidence?

Oral Presentations 3 (Clinical Pharmacology) Chair: Romual BELLMANN (Innsbruck)

09:15–09:30

Paula SCHWARZ (Wien):

Blood–brain barrier: peptide shuttles for drug delivery into the CNS

09:30–09:45

[A1.4](#)

Marcel RAINER (Zürich):

Investigating drug–drug interactions and associated adverse reactions in Switzerland and Austria: an analysis of VigiBase data

09:45–10:00

[A1.3](#)

Anselm JORDA (Wien):

Nirmatrelvir-ritonavir and molnupiravir for the outpatient treatment of Covid-19: a population-based cohort study

10:00–10:15

[A1.5](#)

Matthias JACKWERT (Wien): **Measurement of the activity of multidrug resistance-associated proteins in different human tissues with long axial field-of-view PET imaging**

10:15–11:45

Poster and Coffee: Poster Session 2

[Guided Poster Tour 2](#)

[See next page](#) for list of posters presented in this tour

11:45–12:45

Lunch Snacks

12:45–13:45

APHAR General Assembly

(Members of APHAR only)

12:45–13:15

Hans-Horst Meyer Award

(including presentation by the recipient)

The Hans Horst Meyer Award is sponsored by



13:15–13:45

Heribert Konzett Award

(including presentation by the recipient)

The Heribert Konzett Award is sponsored by



13:45

End of Meeting

Poster program continues on next page

Wed 25 Sept

10:15–11:45

Poster and Coffee: Poster Session 2

[Guided Poster Tour 2](#)

Board 1	Abdallah ABDALHADY (Innsbruck): CNS biodistribution study of AAV-transduced neuropeptides upon intrahippocampal delivery in mesial temporal lobe epilepsy
Board 3 A2.1	Jovan BALJAK (Novi Sad): From package information leaflets to understanding: patient perception of drug information
Board 5	Laura Bianka DANNER (Graz): Involvement of CB2 receptors in CD4+ T-cell function in allergy
Board 7 A2.4	Sophie EDTMAYER (Krems): STAT3β modulates interferon signaling in acute myeloid leukemia contributing to patient outcomes
Board 9 A2.5	Federico FERRO (Innsbruck): Neuromodulatory role of VIP/VPAC_{1/2} signaling in stress and anxiety-related circuits of mice
Board 11	Laureta GASHI (Vienna): Linking glucocorticoids, alcohol and the substance P/neurokinin 1 receptor system in the central amygdala
Board 13	Francesco GENTILE (Vienna): Morphological and calcium-imaging study of primary hippocampal neurons and glia co-cultures after induction of paroxysmal depolarization shifts
Board 15	Ulrich GRAF (Vienna): Safety, tolerability and efficacy of an ophthalmic semi-solid hydrogel used as a topical lubricant in patients with dry eye disease and subjects wearing contact lenses
Board 17 A2.8	Theresa HARM (Krems): Changes in peripheral NK cells during metastatic triple-negative breast cancer progression
Board 19 A2.9	Horia C. HERMENEAN (Innsbruck): Ca²⁺ channelopathy associated CACNA1D (CaV1.3) variants cause diverse functional changes in a dominant manner
Board 21 A2.11	Siriwat HONGNAK (Innsbruck): Selective targeting the κ-opioid receptor by diphenethylamines for discovery of potential therapeutics
Board 23 A2.12	Ameya KASTURE (Vienna): D opamine transporter recruits the exocyst complex for post-Golgi trafficking in <i>Drosophila melanogaster</i>
Board 25	Felix KOSTA (Vienna): Diamine oxidase protection against histamine-induced haemodynamic shock in guinea pigs
Board 27	Helmut KUBISTA (Vienna): Neuronal glutaminolysis drives epileptiform discharges <i>in vitro</i>
Board 29 A2.16	Nemanya MARTIĆ (Novi Sad): Off-label administration of drugs in critically-ill newborns at the Institute for Children and Youth Health Care of Vojvodina
Board 31 A2.18	Yuliia NIKONISHYNA (Krems): Autism-associated A749G variant of Cav1.3 Ca²⁺ channels alters morphology of hippocampal and striatal neurons in knock-in mice
Board 33	Mitja Amon POSCH (Innsbruck): Differences of designer receptor exclusively activated by designer drugs (DREADD) signalling preferences compared to wild-type receptors
Board 35	María Ángel RAMÓN DE QUADROS (Vienna): Cyclic peptide modulators of POP-induced alpha-synuclein aggregation
Board 37 A2.21	Nikita SHAH (Vienna): The functional rescue of novel epilepsy-linked missense mutations in the human GABA transporter 1 by pharmacochaperoning
Board 39 A2.22	Philip STEINER (Linz): Thapsigargin induces a non-apoptotic alternative modality of programmed cell death in RBL-1 cells
Board 41	Nataša TOMAŠEVIĆ (Novi Sad): Macrocyclic peptides as novel cannabinoid CB2 receptor modulators
Board 43 A2.23	Didem ÜN (Vienna): The N-terminus of the human creatine transporter 1 is required for its export from the endoplasmic reticulum
Board 45 A2.25	Stefanie WEIB (Krems): STAT3 isoforms – Striking the balance in AML
Board 47 A2.26	Eva Maria ZEBEDIN-BRANDL (Vienna): Pilot study to explore the length, readability and regulatory compliance of informed consent forms in clinical trial applications across the EU

APHAR 2024

SOCIAL PROGRAM

Tue 24 Sept **Riverside Barbecue Dinner**

19:00 –

Riverside Barbecue Dinner

Details will be announced at the meeting!

*Participation is free of charge for registered participants.
Additional tickets can be purchased at the registration desk.*

SPONSORS

Sponsors of APHAR Hans Horst Meyer Award



Sponsor of APHAR Heribert Konzett Award



Associate Members of APHAR



© information

Poster design: © thomasgraz.net

Poster photos: Univ. of Innsbruck

ANSUCHEN UM AUFNAHME
als ordentliches Mitglied

Name:

Zuname

Vorname

Akad. Grad:

Berufstitel:

Ausbildung:

Derzeitiges Arbeitsgebiet:

Institut/Firma:

Anschrift:

Tel: **Fax:**

e-mail:

Dissertant/in (bei gewünschter Aufnahme als Mitglied im Dissertationsstadium bitten wir eine Bestätigung der/des Dissertationsbetreuerin/-betreuers mitzuschicken)

Sektion Klinische Pharmakologie (bei gewünschter Aufnahme als Mitglied in die Sektion Klinische Pharmakologie bitte hier ankreuzen)

* Ich bestätige, dass die APHAR diese Daten gemäß der gültigen Datenschutzrichtlinie der Gesellschaft (http://www.aphar.at/pdfs/Datenschutzrichtlinie_APHAR.pdf) verwenden und verarbeiten darf (*bitte bestätigen).

Datum: _____

Unterschrift: _____

Befürwortendes Mitglied der Gesellschaft:

Name: _____

Unterschrift: _____

Das ausgefüllte und unterschriebene Formular bitte an die Mitgliederverwaltung der APHAR (mitglieder@aphar.at oder lehre-pharmakologie@medunigraz.at) senden.